Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

St. Jude Medical announces TOCCASTAR clinical trial meets primary safety and efficacy endpoints at heart rhythm 2014


Wednesday, 7 May 2014 05:44pm EDT 

St. Jude Medical Inc:Announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society's 35 Annual Scientific Sessions in San Francisco.Results from the first prospective, randomized study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation met primary endpoints and supplement the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.Says TOCCASTAR study is a multicenter, non-inferiority study evaluating 300 patients in the U.S. and Europe. 

Company Quote

62.24
-1.22 -1.92%
19 Sep 2014